Ezetimibe
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia
One-Sentence Summary
Ezetimibe is a cholesterol absorption inhibitor originally developed for hypercholesterolemia and mixed dyslipidemia, typically used alone or combined with a statin. The TxGNN model’s top-ranked prediction is Hyperlipoproteinemia, with 50 clinical trials and 19 publications identified — though as the evidence itself notes, this is essentially a validation of the drug’s already-established core indication rather than a genuinely novel repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypercholesterolemia / Mixed Dyslipidemia (established use; no marketing-authorization license text available in this dataset) |
| Predicted New Indication | Hyperlipoproteinemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in the DrugBank record for this drug (data gap). Based on the evidence pack’s own repurposing rationale, however, ezetimibe’s known pharmacology is well established: it selectively inhibits the NPC1L1 (Niemann-Pick C1-Like 1) transporter at the intestinal brush border, blocking dietary and biliary cholesterol absorption and thereby lowering LDL-cholesterol.
Hyperlipoproteinemia is a broad clinical term for elevated lipoprotein/cholesterol levels — essentially the same disease space as ezetimibe’s known, already-approved use. The evidence source itself flags this explicitly: this is the drug’s existing core indication surfacing as a high-confidence prediction, not a new therapeutic direction. It functions as a sanity-check / positive-control case for the TxGNN model rather than a discovery.
Mechanistically the fit is direct and non-speculative: NPC1L1 inhibition reduces LDL-C, which is precisely the pathophysiological target in hyperlipoproteinemia. The same logic extends to the closely related “familial hypercholesterolemia” prediction (rank 2), where ezetimibe is already guideline-recommended as add-on therapy when statins alone are insufficient. Worth noting separately: among the lower-ranked candidates, “HIV infectious disease” (rank 5) is evidence-backed but reflects treatment of antiretroviral-associated dyslipidemia rather than any antiviral effect — a distinction to keep clear if that signal is pursued later.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00271817 | Phase 3 | Completed | 1220 | Efficacy/safety of ezetimibe/simvastatin + extended-release niacin in Type IIa/IIb hyperlipidemia |
| NCT03884452 | Phase 3 | Completed | 50 | Ezetimibe 10mg added to atorvastatin or simvastatin in homozygous familial hypercholesterolemia |
| NCT02748057 | Phase 3 | Completed | 135 | Long-term (52-week) safety/tolerability of ezetimibe+rosuvastatin in Japanese patients with inadequate LDL-C control |
| NCT01043380 | Phase 4 | Completed | 245 | PRECISE-IVUS: coronary plaque regression, cholesterol absorption vs. synthesis inhibitor (surrogate endpoint) |
| NCT00651560 | Phase 3 | Completed | 167 | Vytorin (ezetimibe/simvastatin) vs. atorvastatin, ATP-III goal attainment in dyslipidemia |
| NCT00093899 | Phase 3 | Completed | 611 | Ezetimibe/simvastatin + fenofibrate coadministration in mixed hyperlipidemia |
| NCT00092560 | Phase 3 | Completed | 587 | Fenofibrate + ezetimibe coadministration, cholesterol-lowering efficacy/safety in mixed hyperlipidemia |
| NCT00704535 | N/A | Completed | 4105 | Post-marketing surveillance of ezetimibe safety/tolerability/efficacy in Filipino patients |
| NCT00704444 | N/A | Completed | 11332 | 12-week designated drug-use investigation of Zetia (Japan), mono- and combination therapy |
| NCT00705211 | N/A | Completed | 1794 | 52-week long-term designated drug-use investigation of Zetia (Japan) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40347969 | 2025 | RCT | Lancet | TANDEM Phase 3 trial: obicetrapib + ezetimibe fixed-dose combination for LDL-C reduction |
| 41206969 | 2026 | RCT | JAMA | Oral PCSK9 inhibitor enlicitide in heterozygous FH; notes many patients fail to reach LDL-C goals on current therapies incl. ezetimibe |
| 25939291 | 2015 | Review | Cardiology Clinics | Familial hypercholesterolemia overview; ezetimibe among core LDL-C-lowering treatments |
| 38599725 | 2024 | Review | Indian Heart Journal | FH epidemiology, underdiagnosis, and treatment overview |
| 34480646 | 2021 | Review | Current Cardiology Reports | FH global burden, diagnosis, risk estimation, and management approaches |
| 29219151 | 2017 | Review | Nature Reviews Disease Primers | Comprehensive FH primer covering genetics, diagnosis, and treatment |
| 23956253 | 2013 | Review/Guidance | European Heart Journal | EAS consensus statement on FH underdiagnosis/undertreatment and clinician guidance |
| 35593194 | 2022 | Review | J Cardiovasc Pharmacol Ther | Comprehensive review of PCSK9 inhibitors in context of statin-intolerant/FH patients |
| 37762244 | 2023 | Review | Int J Mol Sci | Pathophysiology, diagnosis, and treatment of postprandial hyperlipidemia |
| 33766264 | 2021 | Review | J Am Coll Cardiol | New and emerging LDL-C/ApoB-lowering therapies beyond statins and ezetimibe |
EU Market Information
Ezetimibe currently has no marketing authorization on file in this dataset (0 licenses, market status: Not Marketed). No authorization number, product name, or approved indication text is available to report.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The evidence base easily meets the L1 threshold (multiple completed Phase 3 RCTs directly testing ezetimibe, including combination and long-term safety trials), but this reflects confirmation of ezetimibe’s already-established lipid-lowering indication rather than a novel repurposing opportunity — the guardrail is against treating this as new clinical territory.
To proceed, the following is needed:
- TFDA/EMA SmPC warnings, precautions, and contraindications (currently a blocking data gap — required before any safety pre-assessment)
- Confirmed mechanism-of-action documentation from DrugBank
- Verification of actual marketing-authorization status in the target jurisdiction, since this dataset shows zero licenses on file for an otherwise globally marketed drug
- Clarification of whether “Hyperlipoproteinemia” should be treated as a label-extension question at all, given its substantial overlap with ezetimibe’s existing approved use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.